A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Seletalisib (Primary)
- Indications Immunological disorders; Plaque psoriasis; Sjogren's syndrome
- Focus Adverse reactions
- Sponsors UCB
- 17 Jun 2017 Results of human PK profile (from two phase I studies) along with in-vitro cell-based studies on blood samples presented at the 18th Annual Congress of the European League Against Rheumatism
- 04 Feb 2017 Results of two phase I studies (NCT02303509 and NCT02207595), published in the European Journal of Clinical Pharmacology
- 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov